VVD-130037(BAY-3605349) is an orally available covalent small molecule activator of Kelch-like ECH associated protein 1 (KEAP1), which provide enhanced cellular degradation of nuclear factor-erythroid 2 p45-related factor 2 (NRF2) resulting in significant inhibition of tumor growth in advanced solid tumors.

VVD-130037(BAY-3605349) is an orally available covalent small molecule activator of Kelch-like ECH associated protein 1 (KEAP1), which provide enhanced cellular degradation of nuclear factor-erythroid 2 p45-related factor 2 (NRF2) resulting in significant inhibition of tumor growth in advanced solid tumors.

NDI-101150 is a potent HPK1 (MAP4K1) inhibitor that selectively activates immune cells such as T cells, B cells, and dendritic cells. It significantly inhibits tumor growth and induces complete tumor regression in the EMT-6 mouse model.

NDI-101150 is a potent HPK1 (MAP4K1) inhibitor that selectively activates immune cells such as T cells, B cells, and dendritic cells. It significantly inhibits tumor growth and induces complete tumor regression in the EMT-6 mouse model.

NDI-101150 is a potent HPK1 (MAP4K1) inhibitor that selectively activates immune cells such as T cells, B cells, and dendritic cells. It significantly inhibits tumor growth and induces complete tumor regression in the EMT-6 mouse model.

NDI-101150 is a potent HPK1 (MAP4K1) inhibitor that selectively activates immune cells such as T cells, B cells, and dendritic cells. It significantly inhibits tumor growth and induces complete tumor regression in the EMT-6 mouse model.

BMS-986397 (CC-91633) is a potent and selective thalidomide-derived molecular glue degrader of CK1α and a modulator of CRBN E3 ubiquitin ligase. As a first-in-class CELMoD agent, it exhibits strong anti-leukemic activity in AML (Acute Myeloid Leukemia) and HR-MDS (High-Risk Myelodysplastic Syndrome) models, with enhanced efficacy and potency for hematologic malignancies and immunomodulation.

BMS-986397 (CC-91633) is a potent and selective thalidomide-derived molecular glue degrader of CK1α and a modulator of CRBN E3 ubiquitin ligase. As a first-in-class CELMoD agent, it exhibits strong anti-leukemic activity in AML (Acute Myeloid Leukemia) and HR-MDS (High-Risk Myelodysplastic Syndrome) models, with enhanced efficacy and potency for hematologic malignancies and immunomodulation.

BMS-986397 (CC-91633) is a potent and selective thalidomide-derived molecular glue degrader of CK1α and a modulator of CRBN E3 ubiquitin ligase. As a first-in-class CELMoD agent, it exhibits strong anti-leukemic activity in AML (Acute Myeloid Leukemia) and HR-MDS (High-Risk Myelodysplastic Syndrome) models, with enhanced efficacy and potency for hematologic malignancies and immunomodulation.

BMS-986397 (CC-91633) is a potent and selective thalidomide-derived molecular glue degrader of CK1α and a modulator of CRBN E3 ubiquitin ligase. As a first-in-class CELMoD agent, it exhibits strong anti-leukemic activity in AML (Acute Myeloid Leukemia) and HR-MDS (High-Risk Myelodysplastic Syndrome) models, with enhanced efficacy and potency for hematologic malignancies and immunomodulation.